Evidence map›Paper›PMID 28699792›Full record

ReviewExpert opinion on drug discovery2017

Novel approaches to the design of bioavailable melanotropins.

Yang Zhou, Minying Cai

Abstract readReview
In one paragraph

Review in Expert opinion on drug discovery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Yang Zhoua Department of Chemistry and Biochemistry , University of Arizona , Tucson , AZ USA.
Minying Caia Department of Chemistry and Biochemistry , University of Arizona , Tucson , AZ USA.
University of Arizona · US

Funding

Supplement for "Designing Novel Melanotropins for New Applications for the Melanocortin System"R01GM108040 · NIGMS · UNIVERSITY OF ARIZONA · PI CAI, MINYING, HRUBY, VICTOR J · 2014 to 2017
$1.2M
NIGMS NIH HHS R01 GM108040
6 · The paper itself

Abstract

introductionThe melanocortin system is a primordial and critical system for survival, involved in a wide variety of physiological functions. It includes melanocortin receptors (MCRs) and melanotropin ligands (MCLs). MCRs are important drug targets that can regulate several key physiological processes. Extensive efforts have been made to develop peptide and peptidomimetics targeting melanocortin receptors including MC1R, MC3R, MC4R and MC5R. Most research is focused on developing potent and selective melanotropins. However, developing bioavailable melanotropins remains challenging. Areas covered: Herein, the authors summarize promising strategies for developing bioavailable MCLs by using cyclized N-methylated melanotropins, and using cyclotide and tetrapeptide as templates. They discuss their unique advantages in oral availability and targeting MCRs in the central nervous system or in peripheral tissues. Finally, they discuss the observed differences in thepharmacology of MCRs between in vitro and in vivo tests. Expert opinion: N-methylated cyclized melanotropins have great potential to become bio- available drugs targeting MCRs in the brain, while MCR-grafted cyclotides tend to target MCRs in peripheral tissue. A better understanding of the biased signaling process is a new challenge and opportunity for the future discovery of bioavailable MCLs.

Indexed as

Drug DesignAnimalsBiological AvailabilityCyclotidesHumansLigandsMelanocyte-Stimulating HormonesPeptidesPeptidomimeticsReceptors, MelanocortinTissue DistributionCyclotidesLigandsMelanocyte-Stimulating HormonesPeptidesPeptidomimeticsReceptors, Melanocortinbioavailable peptidecyclized peptidecyclotideN-methylated peptide

Identifiers

PMID28699792
PMCPMC5953761
OpenAlexW2735306417

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.